Kingchem Reports Strong Sales Growth and Improved Profitability Amid Cost Reductions

Kingchem (Liaoning) Life Science Co., Ltd., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation that reflects notable shifts in its financial metrics. The company reported net sales of CNY 174.75 million for the quarter ending March 2025, showcasing a growth rate of 42.66%. This positive trend is further supported by a pre-tax profit of CNY 55.56 million, which has increased by 176.83%, and a net profit of CNY 46.83 million, marking a growth of 179.72%. Additionally, Kingchem has experienced a significant reduction in raw material costs, which fell by 47.43% year-over-year. The inventory turnover ratio reached its highest at 1.75%, indicating efficient management of stock. The operating profit also peaked at CNY 48.75 million, with an operating profit margin of 27.9%. Despite some challenges, such as a decline in net profit over the nine-month period and a high debt-equity ratio, the overall valuation has been revised to an attractive level, with a price-to-book value of 0.33. This adjustment in evaluation underscores the company's evolving financial landscape and market position. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.